HAO (Haoxi Health Technology) Debt-to-EBITDA : 0.63 (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Haoxi Health Technology Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Haoxi Health Technology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.83 Mil. Haoxi Health Technology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.37 Mil. Haoxi Health Technology's annualized EBITDA for the quarter that ended in Jun. 2024 was $1.92 Mil. Haoxi Health Technology's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 0.63.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Haoxi Health Technology's Debt-to-EBITDA or its related term are showing as below:

HAO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.67 Med: 0.85 Max: 1.86
Current: 0.68

During the past 4 years, the highest Debt-to-EBITDA Ratio of Haoxi Health Technology was 1.86. The lowest was 0.67. And the median was 0.85.

HAO's Debt-to-EBITDA is ranked better than
68.7% of 655 companies
in the Media - Diversified industry
Industry Median: 1.58 vs HAO: 0.68

Haoxi Health Technology Debt-to-EBITDA Historical Data

The historical data trend for Haoxi Health Technology's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haoxi Health Technology Debt-to-EBITDA Chart

Haoxi Health Technology Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

Debt-to-EBITDA

1.01

1.86

0.70

0.67

Haoxi Health Technology Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-EBITDA	Get a 7-Day Free Trial			1.66	0.54	0.59	0.63	0.63

Competitive Comparison of Haoxi Health Technology's Debt-to-EBITDA

For the Advertising Agencies subindustry, Haoxi Health Technology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Haoxi Health Technology's Debt-to-EBITDA Distribution in the Media - Diversified Industry

For the Media - Diversified industry and Communication Services sector, Haoxi Health Technology's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Haoxi Health Technology's Debt-to-EBITDA falls into.

Save Embed

;

Save Embed

;

Haoxi Health Technology Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Haoxi Health Technology's Debt-to-EBITDA for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.834	+	0.368)	/	1.787
	=	0.67

Haoxi Health Technology's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.834	+	0.368)	/	1.918
	=	0.63

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2024) EBITDA data.

Haoxi Health Technology (NAS:HAO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Haoxi Health Technology Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Haoxi Health Technology's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Haoxi Health Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Communication Services » Media - Diversified » Haoxi Health Technology Ltd (NAS:HAO) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Room 801, Tower C, Floor 8, Building 103, Building 103, Huizhongli, Chaoyang, Beijing, CHN

Website

https://www.haoximedia.com

Haoxi Health Technology Ltd is an online marketing solution provider in China, with an advertiser client base mainly in the healthcare industry. Haoxi has been rooted in the field of local online effect marketing for many years, serving customers in various industries at home and abroad, and its main business is the medical industry. It generates its revenue by providing one-stop online marketing solutions, in particular online short video marketing solutions, to advertisers through its media partners. The company provides customized marketing solutions by planning, producing, placing, and optimizing online ads, especially online short video ads, to help its advertisers acquire, convert, and retain ultimate consumers on various online media platforms.